Kornimate/medical-research-clean huggingface dataset:
gustatory dysfunction among a sample of depressed egyptian adults under anti-depressants therapy

Conditions: Taste Disorders

Summary: - assess gustatory thresholds among a sample of depressed egyptian adults (age from 20 to 50 years old) under anti-depressants therapy ( for at least 3 months) using filter paper disc(fpd) method through a scoring system. - determine the taste intensity at supra-threshold among these patients using a psychophysical method through a scoring system. - identify possible modulators for developing gustatory dysfunction among these patients using a questionnaire ( appendix) with a binary measuring unit (yes/no).

peco * p population: depressed egyptian adults under anti-depressants therapy * e1 exposure 1: commonly prescribed tricyclic antidepressants (imipramine, amitriptyline, clomipramine hcl) * e2 exposure 2: commonly prescribed selective serotonin re-uptake inhibitors antidepressants ( fluoxetine, fluvoxamine, sertraline, citalopram, paroxetine) * c control (non exposure) : non-pharmacological treatment ( psychotherapy) * o outcome: primary 1ry : assess gustatory thresholds among a sample of depressed egyptian adults (age from 20 to 50 years old) under anti-depressants therapy ( for at least 3 months) using filter paper disc(fpd) method through a scoring system. secondary 2ry: - determine the taste intensity at supra-threshold among these patients using a psychophysical method through a scoring system. - identify gustatory dysfunction modulators among these patients using a questionnaire ( appendix) with a binary measuring unit (yes/no).

Eligibility criteria:
inclusion criteria: * depressed egyptian adults under antidepressants therapy for at least 3 months/non-pharmacological treatment( psychotherapy) * age from 20 to 50 years old exclusion criteria: * antipsychotics * hypnotics * anticonvulsants * ages other than the mentioned * olfactory dysfunction * chemosensory dysfunction
two years survival rate of class ii art restorations in primary molars using two ways to avoid saliva contamination

Conditions: Dental Caries

Summary: aim: to evaluate influence of two methods to avoid saliva contamination on the survival rate of atraumatic restorations in primary molars. 232 children, aged between 6-7 years, of both genders, were selected having one primary molar with a proximal dentine lesion. the children were randomly divided into two groups: a control group with class ii art restoration made using cotton rolls and an experimental group using rubber dam. the restorations were made and they were followed up every six months. after two years, the results were compilated and analyzed.

to evaluate influence of two methods to avoid saliva contamination on the survival rate of atraumatic restorations in primary molars. 232 children, aged between 6-7 years, of both genders, were selected having one primary molar with a proximal dentine lesion. the children were randomly divided into two groups: a control group with class ii art restoration made using cotton rolls and an experimental group using rubber dam. the restorations were made and they were followed up every six months. after two years, the results were compilated and analyzed.

Eligibility criteria:
inclusion criteria: * children of both genders enrolled in school, * children aged between 6 and 7 years, * having cavity with access to art hand instruments, * cavity with a mesio-distal maximum dimension of 1mm and a buccal-lingual maximum dimension of 2mm length, measured on the oclusal surface, * proximal surface of the adjacent tooth should be unimpaired, without visible lesions, exclusion criteria: * cavity lesions having pulpal involvement, swelling, fistula or pain were not included in the study, * children out of the age range,

Keywords: dental caries atraumatic restorative technique
evolution of the therapeutic care in metastatic breast cancer from 2008

Conditions: Metastatic Breast Cancer

Summary: the epidemiological strategy and medical economic (esme) breast cancer database is a multicenter real life database using a retrospective data collection process across 18 french comprehensive cancer centers (fccc) spread over 20 sites. this database compiles data from patient's electronic medical records (emr).

this database compiles existing data retrieved fromp patient's electronic medical records (emr) across the 18 french comprehensive cancer centers spread over 20 sites. . the database includes data related to patient demographics, tumor characteristics (diagnosis, histology, relapses, metastatic disease, etc.), treatments (dates, inn, route of administration, treatment protocols, reason for termination, etc.), and clinical events. data is collected at each participating site by technicians who are specifically trained for the project using an electronic data collection (edc) tool. data imported into the final database are controlled, recoded, and harmonized before import according to the data management plan. all coding procedures are predefined by the data manager. there is no transmission of individual data; all data are centralized within each center using a shared anonymous format. all data is exclusively obtained retrospectively; no attempts are made to recover non available data from the patient's medical record by contacting healthcare providers or patients. cases selected to enter the esme mbc data platform fulfill specific criteria: (1) male or female ≥18 years old (2) metastatic breast cancer (3) with first metastasis treated (either completely or partially) at a participating site from january 2008 onwards.treatment strategies considered include radiotherapy, chemotherapy, targeted therapy and endocrine therapy.

Eligibility criteria:
inclusion criteria : * 18 years old patient * patient receiving chemotherapy, targeted therapy, immunotherapy, radiation therapy and hormonotherapy in a french comprehensive cancer center. exclusion criteria : none

Keywords: metastatic breast cancer observational study survival real world data real life setting
development of the oncology opportunity cost assessment tool

Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm

Summary: this study develops and tests an instrument to measure opportunity costs called the oncology opportunity cost assessment tool (oocat) in cancer patients. patients experience significant costs, both direct financial as well as indirect costs, associated with seeking cancer treatment. while the direct financial impact of care on patients is receiving increased attention, other important consequences, such as opportunity cost, remain largely unmeasured. opportunity cost is an economics term that refers to the loss of potential benefits from other options when one option is chosen - if resources are used for one purpose, they are no longer available for the next best option. the information and knowledge gained from this study may help researchers develop the oocat, which may allow them to understand the opportunity cost of treatment for each patient. the oocat may then be used to determine not just the best medications for patients, but also the best comprehensive treatment plan that will allow them to get the right treatment in the right place at the right time.


Eligibility criteria:
inclusion criteria: * treated for cancer at one of the 3 participating sites (jefferson center city, jefferson methodist hospital, jefferson abington) * english speaking * able to attend and participate in a focus group exclusion criteria: * treated at a jefferson site other than the ones mentioned * non-english speaking
combination of supplements for treating autistic spectrum disorder

Conditions: Autism Spectrum Disorder (ASD

Summary: a pilot study to compare the efficacy of a combination of apitherapy supplements versus placebo in children with autistic spectrum disorder.

a prospective, double-blind, placebo-controlled, crossover, multicentre clinical study which will enrol up to 45 children diagnosed with asd (enrolment will stop when 40 children have completed the study). children ages 3-14 will be tested before and after administering the combination of active substances (3 months) and placebo (3 months). the duration of participation in the study for each child will be 6 months. the supplements tested consist of three products - a combination of apitherapy and plant extracts - which have been approved for sale as individual supplements for more than 5 years in romania - apicol 12 gamma, laptisor de matca activat (royal jelly) and telom r cerebral. participation in the study is free and all children will be comparatively evaluated with the atec and asrs scales and three sets of blood tests.

Eligibility criteria:
inclusion criteria: * age 3-14 years * diagnosed with typical or atypical autism spectrum disorder (f84.0 or f84.1) and received at least one therapeutic intervention before enrolling * the ability to follow an oral treatment, with tid/bid/qd administration * the availability to perform 3 sets of blood tests at a clinical laboratory within 6 months (initial, at 3- and 6-months) * the availability to perform 3 visits to the investigator and 3 psychometric evaluations within 6 months exclusion criteria: * patients enrolled in another interventional clinical trial currently or which ended less than 1 month prior to enrolling in this study * known allergy to hive products or one of the substances studied * inability to perform the study requirements (3 visits to the investigator, 3 psychometric assessments, 3 sets of blood tests) * diagnosis of diabetes * history of seizures/epilepsy * administration of anticoagulants, antiplatelets, thrombolytic agents, low molecular weight heparins, anticonvulsants, insulin, monoamine oxidase inhibitors, non-steroidal anti-inflammatory drugs or thiazide diuretics * allergy to celery and other plants of the fam. apiaceaea (umbelliferae) * abnormally elevated baseline (at v1) values of ferritin, homocysteine, hgba1c, esr

Keywords: autistic spectrum disorder apitherapy brain aromatase
biological collection from samples from the gut microbiota in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine (carbamicrobiota)

Conditions: Bone Infection; Joint Infection

Summary: optimal surgical therapy (debridement in chronic osteomyelitis; device exchange in patients with chronic prosthetic joint infection (pji)) could be sometimes non-feasible, especially in the elderly population. therefore, a medical therapy with oral prolonged suppressive antibiotic therapy (psat) seems to be an option to prevent recurrence and prosthesis loosening. unfortunately, some patients are infected with resistant pathogens for which oral antibiotics are not suitable. subcutaneous (sc) administration of injectable intravenous antibiotics as prolonged suppressive antibiotic therapy could be a convenient way to limit catheter-related complications and facilitate ambulatory care. however, there are few data concerning the development of resistance under subcutaneous prolonged treatment with betalactamine. the aim of this study is just to constitute a biological collection from samples from the gut microbiota in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. later analysis will be led on those samples to detect the acquisition of resistance or not.


Eligibility criteria:
inclusion criteria: * patients having a bone or joint infection * patients treated by a suppressive subcutaneous antibiotherapy with betalactamine exclusion criteria: * none
validity and reliability of commercially available metabolic carts

Conditions: Metabolism and Nutrition Disorder

Summary: the validity (by alcohol burning and gas infusions) and reliability (day-to-day variability in healthy subjects) of six metabolic carts will be compared.


Eligibility criteria:
inclusion criteria: * healthy male or female. * age 18-65 y. * bmi between 18.5 kg/m2 and 40 kg/m2 (inclusive). * are willing to fast and not consume non-caloric stimulant for 10h before the assessments, and during the stay in the center. * are willing to avoid moderate or vigorous physical activity during 24h before the visits. exclusion criteria: * smoking or use of tobacco products within the last 3 months * diagnosed with diabetes. * previous bariatric surgery (or other surgeries) for obesity or weight loss. * use of medications affecting metabolism or sleep. * history of neurological disease. * history of cardiovascular disease, including hypertension, or other chronic diseases. * pregnant, planning to become pregnant, or breastfeeding * claustrophobia impeding to stay calm under a plastic canopy.
combination of cetuximab with afatinib for patient with egfr mutated lung cancer

Conditions: Non Small Cell Lung Cancer

Summary: until recently, the first line treatment of metastatic non small cell lung cancer (nsclc) was a platine-based chemotherapy. it has been changed by the discovery of egfr (epidermal growth factor receptor) mutations and associated treatment with tyrosine kinase inhibitor (tki) of egfr. the superiority of egfr tki over chemotherapy for egfr mutated patients has been proved in several phase iii trials with gefitinib, erlotinib or afatinib. nevertheless, all patients will progress after 9 to 12 months of treatment due to the appearance of a treatment resistance. afatinib is an irreversible egfr tki. it binds to its receptor permanently.contrary to erlotinib and gefitinb which inhibits only egfr, afatinib inhibits the kinase activity of all her family (human epidermal growth factor receptor). nevertheless, there is no proof that afatinib delay the appearance of resistance. cetuximab is a monoclonal antibody which binds specifically with egfr. the double inhibition of egfr by afatinib and cetuximab has demonstrated its efficacy in pre-clinical models. the hypothesis of this study is that the combination between cetuximab and afatinib will permit to delay or decrease the appearance of resistances.


Eligibility criteria:
principal inclusion criteria: * stage iii or iv nsclc, non irradiable non operable * non squamous nsclc histologically or cytologically confirmed * no previous treatment of nsclc * egfr mutation (exon 19 deletion, l858r mutation, g719x , l861q or s768i mutations or exon 19 insertion) * presence of at least one lesion that can be measured * ps 0 or 1 principal exclusion criteria: * symptomatic brain metastasis or requiring immediate radiotherapy * t790m mutation or exon 20 insertion * radiotherapy less than 2 weeks prior randomization including symptomatic radiotherapy * interstitial pneumopathy

Keywords: egfr lung cancer
dexmedetomidine vs midazolam on resting energy expenditure in critically ill patients

Conditions: Mechanical Ventilation; Dexmedetomidine; Midazolam; Sedation

Summary: the aim of this study is to compare the effect of dexmedetomidine on resting energy expenditure in relation to the midazolam in critically ill patients using indirect calorimetry

caloric needs in critically-ill patients fluctuate significantly over the course of the disease which might expose patients to either malnutrition or overfeeding. malnutrition is associated with deterioration of lean body mass, poor wound healing, increased risk of nosocomial infection, and weakened respiratory muscles. on the other hand overfeeding in medically compromised patients can promote lipogenesis, hyperglycemia, and exacerbation of respiratory failure. many factors may affect the resting energy expenditure (ree) through manipulation of oxygen consumption (vo2). sedatives are important contributors to reduction of ree. the postulated mechanism of sedative-induced reduction of vo2 is inhibition of circulating catecholamine and pro-inflammatory cytokines. dexmedetomidine is a highly selective α2-adrenoceptor agonist. stimulation of the α2-adrenoceptor in the central nervous system causes a 60-80% reduction in sympathetic outflow and endogenous catecholamine levels. it was found that perioperative use of α2 agonists decreased sympathetic activity with subsequent reduction of vo2 and ree. moreover, dexmedetomidine, has some anti-inflammatory effect by inhibiting the pro-inflammatory cytokines which may cause additional reduction of ree in critically ill patient. midazolam is another important sedative that is frequently used in critically-ill patient. terao et al. found that increasing the depth of sedation using midazolam, decreased oxygen consumption and ree. however, it remains unclear whether the effect of midazolam on ree is related to the drug itself or to the depth of sedation. there is no direct comparison in the literature between dexmedetomidine and midazolam on ree.

Eligibility criteria:
inclusion criteria: * the study will be designed to recruit 30 critically-ill patients who will be admitted to the surgical icu for ventilatory support and will be expected to continue for 2 days or longer. exclusion criteria: * age \< 18 years old. * pregnant patient. * serious central nervous system pathologies (traumatic brain injury, acute stroke, uncontrolled seizures). * patient who will require fraction of inspired oxygen more than 0.6. * air leak from the chest tube. * patient with body temperature \> 39 celsius. * acute hepatitis or severe liver disease (child-pugh class c). * left ventricular ejection fraction less than 30%. * heart rate less than 50 beats/min. * second or third degree heart block. * systolic pressure \< 90 mmhg despite of infusion of 2 vasopressors. * patients with known endocrine dysfunction. * patient with hypothermia * patient on positive end expiratory pressure more than 14 cmh2o
a comprehensive optical blood pressure assessment tool to identify cases of unscreened hypertension across an active population in the u.s.

Conditions: Hypertension

Summary: to screen for and identify subjects with potential undiagnosed hypertension using an optical blood pressure monitoring device across an active workforce population in the us (nucor employees).

100 voluntary nucor facility employees with no previous diagnosis of hypertension will be recruited and will receive an optical blood pressure monitoring device (aktiia g1 device) that is a miniature bracelet placed in the wrist and measure blood pressure continuously without inflating. each participant will wear the device continually during 28 days.

Eligibility criteria:
inclusion criteria: 1. adult subjects aged 25 to 70 years old. 2. people who self-report that they do not have a diagnosis of hypertension. 3. people employed as a nucor team member. 4. people who can read and speak english. 5. people who use either an ios or android smart phone. 6. subjects who agree to follow study procedures. 7. subjects who have signed the informed consent form. exclusion criteria: 1. subjects with a known diagnosis of i. atrial fibrillation ii. congestive heart failure iii. heart valve disease iv. pheochromocytoma v. raynaud's disease vi. arm lymphedema. 2. subjects who take insulin. 3. subjects who are on hemodialysis. 4. women who are known to be pregnant. 5. subjects whose arms shake uncontrollably or are paralyzed (cannot move). 6. subjects who do not have two arms. 7. subjects with upper arm circumference \ 42cm. 8. subjects with wrist circumference \> 23cm.

Keywords: hypertension blood pressure
bladder neck surgery in children with neurogenic bladder

Conditions: Incontinence, Urinary; Bladder Dysfunction; Spina Bifida; Neurogenic Bladder

Summary: surgical outcomes of bladder neck surgery in children with neurogenic bladder. consequences on bladder voiding.

surgical outcomes of bladder neck surgery in children with neurogenic bladder: quality of voiding: spontaneous, need for catheterization, or incontinence. other surgical complications.

Eligibility criteria:
inclusion criteria: * patients, with neurogenic bladder and younger than 18 years old ,who underwent a bladder neck procedure exclusion criteria: * patients, with neurogenic bladder and older than 18 years old ,who underwent a bladder neck procedure

Keywords: bladder neck surgery children surgical outcomes retrospective study
peng vs sifi block for positioning pain during spinal anesthesia

Conditions: Hip Fractures; Acute Post Operative Pain; Nerve Block; Spinal Anesthesia

Summary: this study aims to compare the effectiveness of preoperative ultrasound-guided suprainguinal fascia iliaca compartment block (sficb) and pericapsular nerve group block (peng) in preventing positioning pain during spinal anesthesia in patients who are scheduled for surgery due to hip fracture.

patients to whom an analgesic block was placed (either peng or sifi compartment analgesic block) to ameliorate positioning pain during spinal anesthesia for hip fracture surgery will be enrolled after written consent is obtained. patients will be asked to report their pain intensity while sitting and their sitting angle will be measured. patients will be observed for any possible complications( last, allergic reactions, hypotension, bradycardia). pain intensity will then again be questioned postoperatively along with analgesic consumption at the 24th hour. patients will be arranged into two cohorts according to the block (peng vs sifi) and the data obtained will be compared between two cohorts.

Eligibility criteria:
inclusion criteria: * adults with a hip fracture * who were scheduled to undergo surgery with spinal anesthetics * has no neurologic disorders that impair cooperation (e.g dementia) * has no true allergies to local anesthetics * has no contraindications for regional or neuraxial anesthesia (e.g bleeding diathesis, severe aortic stenosis) exclusion criteria: * childer under the age of 18 * patients scheduled to undergo surgery with general anesthetics * refusing to participate * allergies to local anesthetics * any neurologic disorder that impairs patient cooperation * any contraindication to regional or neuraxial anesthetics
survey of procedures and resources for initiating treatment of hiv in africa-zambia

Conditions: HIV; Antiretroviral Therapy

Summary: in its 2017 revision of the global guidelines for hiv care and treatment, the world health organization (who) called for rapid or same-day initiation of antiretroviral treatment (art) for eligible patients testing positive for hiv. however, to date neither the who nor the zambia ministry of health has provided detailed guidance on how to implement this recommendation. in sub-saharan africa, where most hiv patients are located, studies continue to document high losses of treatment-eligible patients from care before they receive their first dose of antiretroviral medications (arvs). among facility-level reasons for these losses are treatment initiation protocols that require multiple clinic visits and long waiting times before a patient who tests positive for hiv is dispensed an initial supply of medications. there is very little published evidence on the practical details of the process and the extent to which it varies by facility, setting, or country. without a robust baseline evidence base, it is challenging to identify opportunities for making improvements. the sprint (survey of procedures and resources for initiating treatment of hiv in africa) study will begin to develop this evidence base. sprint will combine a facility-level description of the standard of care with a retrospective record review of patients who recently initiated art at the study sites. data will be collected from 12 health facilities in zambia. the survey will elicit detailed information about current procedures through structured interviews with clinic staff at the selected health facilities. the record review for a retrospective cohort of patients eligible for art will estimate actual numbers of clinic visits, services provided, and duration of the steps for treatment initiation from start to finish. sprint is expected to identify differences in approaches to treatment initiation and potential opportunities for improvement.


Eligibility criteria:
inclusion criteria: * ≥18 years old * hiv-positive exclusion criteria: * pregnant